2,4-pyrimidinediamine compounds and prodrugs and their uses
View Patent ↗The present disclosure provides biologically active 2,4-pyrimidinediamine compounds of formulae (I)-(III): and salts thereof, compositions comprising these compounds, and methods of using these compounds in a variety of applications.
1. A compound of any of formulae (I)-(III):
or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1 , having formula (I):
or a pharmaceutically acceptable salt thereof.
3. The compound according to claim 1 , having formula (II):
or a pharmaceutically acceptable salt thereof.
4. The compound according to claim 1 , having formula (III):
or a pharmaceutically acceptable salt thereof.
5. A pharmaceutically acceptable salt of a compound according to claim 1 .
6. A mono- or di-sodium salt, mono- or di-potassium salt, mono- or di-lithium salt, calcium salt, magnesium salt, ammonium salt of a compound according to claim 1 .
7. A mono- or di-trifluoroacetic acid salt, p-toluenesulfonic acid salt, hydrochloride salt, benzenesulfonic acid salt, or ethanesulfonic acid salt of a compound according to claim 1 .
8. A pharmaceutical composition comprising a compound or salt according to claim 1 and an acceptable carrier, excipient and/or diluent.
9. A method of inhibiting cell degranulation in a subject, comprising administering to the subject a pharmaceutically effective amount of a compound or salt according to claim 1 effective to inhibit degranulation.
10. A method of inhibiting an activity of a Syk kinase in a subject, comprising administering to the subject a pharmaceutically effective amount of a compound or salt according to claim 1 effective to inhibit the Syk kinase activity.
11. A method of inhibiting an Fc receptor signal transduction cascade in a subject, comprising administering to the subject a pharmaceutically effective amount of a compound or salt according to claim 1 effective to inhibit the Fc receptor signal transduction cascade.
12. The method according to claim 11 in which the Fc receptor is selected from FcαRI, FcγRI, FcγRIII and FIεRI.
13. A method of inhibiting Syk kinase in a cell comprising contacting a Syk kinase or a cell comprising a Syk kinase with a compound or salt according to claim 1 .
14. A method of inhibiting degranulation of a cell comprising contacting a cell that degranulates with a compound or salt according to claim 1 .
15. A method of inhibiting the Fc receptor signaling cascade comprising contacting a cell expressing an Fc receptor with a compound or salt according to claim 1 .
16. A method of inhibiting the Syk-dependent signal transduction cascade comprising contacting a Syk-dependent receptor or a cell expressing a Syk-dependent receptor with a compound or salt according to claim 1 .